VIARTIS

 

 

 

 

 

PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11th August 2009 - New research

THE MICHAEL J.FOX FOUNDATION FUNDS NINE NEW APPROACHES

The Michael J. Fox Foundation for Parkinson's Research is funding nine new research projects for Parkinson's Disease. All of the nearly four million dollar funding has gone to nine biotech and pharmaceutical companies. For more information read the Press release. The research projects consist of seven "neuroprotective approaches", and two projects concerning the treatment of dyskinesia. The following provides links to the details of each of the nine projects :

*

The pharmacodynamics of ReS9-S7, which concerns early stage research in possible toxicity [1]. The element being researched, alpha-synuclein, has never been shown to cause Parkinson's Disease, but instead has been found only to be affected as a result of it.

*

Exploring curcumin (which is found in a curry spice)  as a possible treatment of Parkinson's Disease [2]. Curcumin is already widely used, due to its ready availability, but has never rid Parkinson's Disease.

*

The effect of novel neuronal nicotinic receptor compounds on dyskinesia [3]. Smoking has the same effect on the nicotinic receptors due its nicotine contact, yet does not rid dyskinesia.

*

Assessment of the therapeutic efficacy of progranulin in a sub-chronic animal model of Parkinsonís disease [4]. Other researchers have already shown that progranulin has no potential in the treatment of  Parkinson's Disease.

*

Validation of LRRK2 as a drug target for treatment of Parkinsonís disease using antisense technology [5]. LRRK2 concerns only a genetic form of Parkinson's Disease.

*

Optimising lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clinical development candidates [6]. LRRK2 concerns only a genetic form of Parkinson's Disease.

*

A novel approach to characterize the distribution of a potentially therapeutic dominant-negative inhibitor of TNF in pre-clinical models of PD, and predict the scalability for an effective delivery of therapy in the human brain [7]. This aims for drugs to be able to by pass  the blood brain barrier. However, Parkinson's Disease has never been shown to be due to a deficiency of the blood brain barrier.

*

Pre-clinical development of a Parkinsonís disease therapy using a glucagon-like peptide (GLP-1) receptor agonist [8]. It is already approved by the FDA, but for diabetes rather than Parkinson's Disease.

*

Optimization of MOR antagonists for the treatment of L-DOPA-induced dyskinesias in Parkinsonís Disease [9]. The theory behind its use does not, even in theory, address the fact that dyskinesia is due to excessive L-dopa.

For more current news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please double click on  E-MAIL NOTIFICATION, or e-mail [email protected].  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports.

                                    

 

    Back to PARKINSON'S DISEASE 

 

 
©2006-2009  Viartis
 
2015-11-10 13:50:01
 
[email protected]